Patents Examined by Paula K. Hutzell
  • Patent number: 6451981
    Abstract: Human lymphocyte-associated cell surface protein LAM-1, which includes domains homologous with binding domains of animal lectins, growth factors, and C3/C4 binding proteins, and the cDNA encoding LAM-1, are described. Antagonists to LAM-1 are used in a method of treating a human patient suffering from a lymphocyte-mobilizing condition which involves administering a therapeutic amount of the antagonist in a non-toxic pharmaceutical carrier substance. Additionally, antibodies that bind human LAM-1 and inhibit cellular adhesion, migration or infiltration into tissues are described.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: September 17, 2002
    Assignee: Dana-Farber Cancer Institute
    Inventor: Thomas F. Tedder
  • Patent number: 6348194
    Abstract: The invention provides a method of reducing the proliferation of a neoplastic cell. The method consists of contacting the neoplastic cell with a cytotoxic or cytostatic binding agent specifically reactive with an aberrantly expressed vesicular membrane associated neoplastic cell specific internalizing antigen. The neoplastic cell specific internalizing anitgen can be selected from the group consisting of lamp-2 and limp II families of lysosomal integral membrane proteins. Also provided is a method of intracellular targeting of a cytotoxic or cytostatic agent to a neoplastic cell population.
    Type: Grant
    Filed: November 13, 1995
    Date of Patent: February 19, 2002
    Assignee: Ixsys Incorporated
    Inventors: William D. Huse, Jeffry D. Watkins
  • Patent number: 6323328
    Abstract: The invention provides a human citrate synthase homolog (HUCS) and polynucleotides which identify and encode HUCS. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HUCS.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: November 27, 2001
    Assignee: Incyte Genomics, Inc.
    Inventors: Jennifer L. Hillman, Preeti Lal, Neil C. Corley, Purvi Shah
  • Patent number: 6320102
    Abstract: The present invention provides nucleic acid sequences from embryo-specific genes. The nucleic acids are useful in targeting gene expression to zygotes and embryos or in modulating embryo development.
    Type: Grant
    Filed: November 17, 1998
    Date of Patent: November 20, 2001
    Assignee: The Regents of the University of California
    Inventors: John J. Harada, Tamar Lotan, Masa-aki Ohto, Robert B. Goldberg, Robert L. Fischer
  • Patent number: 6316694
    Abstract: The invention relates to transformed, embryogenic microspores and progeny thereof characterized by being transformed by Agrobacterium tumefaciens, capable of leading to non-chimeric transformed haploid or doubled haploid embryos that develop into fertile homozygous plants within one generation and containing stably integrated into their genome a foreign DNA, said DNA being characterized in that it comprises at least one gene of interest and at least base pairs within the right border sequence of Agrobacterium T-DNA. The invention furthermore relates to a method for the incorporation of foreign DNA into chromosomes of microspores comprising the following steps: a) infecting of embryogenic microspores with Agrobacteria, which contain plasmid carrying a gene of interest under regulatory control of initiation and termination regions bordered by at least one T-DNA border, b) Washing out and killing the Agrobacteria after co-cultivation.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: November 13, 2001
    Assignee: AgrEvo Canada, Inc.
    Inventors: Mathias Dormann, Hung-Mei Wang, Michael Oelck
  • Patent number: 6310271
    Abstract: A full length choline monooxygenase (CMO) cDNA was cloned from spinach and used to transform plants which do not naturally express CMO. A method is presented to improve stress tolerance of crops following engineering of CMO and BADH in plants that lack glycine betaine accumulation. Also provided are fragments useful as probes to isolate other CMO-type genes, and antisense sequences which inhibit the production of CMO. Reduction of glycine betaine as a consequence of antisense expression of CMO in species naturally accumulating glycine betaine, improves the transgenic plant's tolerance toward pathogens and pests and/or enhances its nutritional quality.
    Type: Grant
    Filed: January 8, 1998
    Date of Patent: October 30, 2001
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Andrew D. Hanson, Bala Rathinasabapathi, Michael Burnet
  • Patent number: 6297425
    Abstract: A novel nucleic acid sequence encoding Aspergillus phoenices oxalate decarboxylase (APOXD) has been determined, as well as the encoded amino acid sequence. The gene and its encoded protein are useful in degrading oxalate, in diagnostic assays of oxalate, and as a selectable marker.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: October 2, 2001
    Assignee: Pioneer Hi-Bred International, Inc.
    Inventors: Christopher J. Scelonge, Dennis L. Bidney
  • Patent number: 6274331
    Abstract: A functional linker for a polypeptide in which two alpha or beta globin-like domains are genetically fused is determined by screening a library of genetically fused polypeptides, in which the linker region is varied, for the ability to participate in the formation of hemoglobin-like protein, as measured by the protein's response to carbon monoxide. In a preferred embodiment, cells expressing the protein turn red as a result of carbon monoxide pressure.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: August 14, 2001
    Assignee: Somatogen, Inc.
    Inventors: Douglas L. Looker, Gary L. Stetler
  • Patent number: 6270777
    Abstract: The present invention provides immunogenic compositions comprising peptides derived from the amino acid sequence of P. aeruginosa for protecting susceptible hosts against diseases caused by bacterial pathogens which secrete a zinc metalloprotease.
    Type: Grant
    Filed: December 20, 1996
    Date of Patent: August 7, 2001
    Assignee: University Technologies International Inc.
    Inventors: Pamela A. Sokol, Cora D. Kooi
  • Patent number: 6268470
    Abstract: The present invention relates to methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers (e.g., colon cancer) in mammals, e.g., humans. The invention is based on the discovery of genes that are differentially expressed in tumor cells relative to normal cells. The genes identified can be used diagnostically or as targets for therapy, and can be used to identify compounds useful in the diagnosis, prevention, and therapy of tumors and cancers.
    Type: Grant
    Filed: December 31, 1997
    Date of Patent: July 31, 2001
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Andrew W. Shyjan
  • Patent number: 6262340
    Abstract: The present invention provides genetically altered plants and plant cells that have been modified to contain expression system(s) capable of expressing a functional polyketide synthase (PKS). The present invention further provides methods of producing PKS and polyketides using these plants and cells.
    Type: Grant
    Filed: July 10, 1998
    Date of Patent: July 17, 2001
    Assignee: Kosan Biosciences, Inc.
    Inventors: Mary C. Betlach, James T. Kealey, Neal Gutterson, Ed Ralston
  • Patent number: 6262341
    Abstract: Compositions and methods for introducing a DNA of interest into a genomic target site are provided. In particular, the methods and compositions involve the use of a combination of target sites for two site specific recombinases and expression of a chimeric recombinase with dual target site specificity. Thus, the compositions comprise novel site-specific recombinases with specificities to multiple target sites, and nucleotide sequences and expression cassettes encoding these recombinases or target sites. The methods involve transforming a eukaryotic cell having target sites for the novel recombinase with a DNA of interest that is flanked by corresponding target sites. Expression of the recombinase results in integration of the DNA of interest into the genome of the cell. The compositions and methods of the invention have use in the construction of stably transformed eukaryotic cells, and in particular, plant cells.
    Type: Grant
    Filed: November 17, 1998
    Date of Patent: July 17, 2001
    Assignee: Pioneer Hi-Bred International, Inc.
    Inventors: Christopher L. Baszczynski, Leszek Alexander Lyznik, William J. Gordon-Kamm, Xueni Guan, Argula Gururaj Rao, Laura A. Tagliani
  • Patent number: 6245899
    Abstract: Disclosed herein is a novel proteinaceous cell density signal molecule (CDS), which is secreted by fibroblastic cells in culture, preferably tendon cells, and which provides a means by which the cells self-regulate their proliferation and the expression of differentiated function. CDS, and the antibodies which recognize them, are important for the development of diagnostics and treatments for injuries and diseases involving connective tissues, particularly tendon. Also disclosed are methods of production and use.
    Type: Grant
    Filed: April 17, 1998
    Date of Patent: June 12, 2001
    Assignee: The Regents of the University of California
    Inventor: Richard I. Schwarz
  • Patent number: 6211432
    Abstract: The present invention relates to any DNA sequence comprising as a coding region all or part of the nucleotidic sequence coding for a mRNA coding coding for a cinnamoyl CoA reductase (CCR) in lucern and/or corn, or all or part of the nucleotide sequence complementary of the latter and coding for an antisense mRNA susceptible of hybridizing with said mRNA. The invention also relates to the use of said sequences for implementing processes for the regulation of lignin biosynthesis in plants.
    Type: Grant
    Filed: July 24, 1998
    Date of Patent: April 3, 2001
    Assignees: Centre National de la Recherche Scientifique, Institut National de la Recherche Agronomique
    Inventors: Alain-Michel Boudet, Magalle Pichon, Jacqueline Grima-Pettenati, Michel Beckert, Pascal Gamas, Jean-François Briat
  • Patent number: 6204001
    Abstract: This invention provides a method for determining whether a compound is capable of suppressing ras functions comprising: (a) contacting an effective amount of the compound with Ha-ras transformed cloned rat embryo fibroblast cells under conditions permitting the compound to suppress ras functions in the cells; and (b) determining the expression or inhibition of certain indicator gene or genes, thereby determining whether the compound is capable of suppressing ras function. This invention further provides the determined compound and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier. This invention also provides methods for generating transcriptional switched Ha-ras transformed cloned rat embryo fibroblast cells. This invention also provides the generated cells and different uses of the cells.
    Type: Grant
    Filed: November 15, 1996
    Date of Patent: March 20, 2001
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Paul B. Fisher, Zao-Zhong Su
  • Patent number: 6187571
    Abstract: The invention relates to the novel use of a sequence coding for a protein capable of degrading oxalic acid to select plant cells which have integrated a gene of interest, and a novel process for selecting, on oxalic acid, cells, calluses or plants transformed by this recombinant DNA.
    Type: Grant
    Filed: October 24, 1995
    Date of Patent: February 13, 2001
    Assignee: Biogemma
    Inventors: Annie Pignard, Bruno Grezes-Besset, René Grison, Michel Schneider
  • Patent number: 6183951
    Abstract: The present invention provides methods based on serological and genetic markers for diagnosing clinical subtypes of Crohn's disease (CD) having characteristic responsiveness to anti-Th1 cytokine therapy. In the methods of the inventions the presence of perinuclear anti-neutrophil antibody (pANCA), the presence of the TNFa10b4c1d3e3 haplotype or the presence TNFa11b4c1d3e3 haplotype each are independently diagnostic of a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy. In addition, the presence of the homozygous TNF-&bgr; 1111 haplotype involving the TNFc, aa13L, aa26 and NcoI loci is independently diagnostic of a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy. The presence of speckling anti-pan polymorphonuclear antibody (SAPPA) is diagnostic of a clinical subtype of CD having a superior clinical response to anti-Th1 cytokine therapy.
    Type: Grant
    Filed: May 12, 1997
    Date of Patent: February 6, 2001
    Assignee: Prometheus Laboratories, Inc.
    Inventors: Scott E. Plevy, Stephan R. Targan, Kent Taylor, Mary J. Barry
  • Patent number: 6184013
    Abstract: This invention provides compounds which are analogs to the hydrolysis transition-state of a cocaine benzoyl ester group. This invention also provides such analogs linked to carrier proteins, and antibodies thereto. This invention further provides pharmaceutical composition for decreasing concentration in a subject using the antibodies produced.
    Type: Grant
    Filed: October 3, 1994
    Date of Patent: February 6, 2001
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Donald W. Landry, Kang Zhao
  • Patent number: 6180855
    Abstract: To provide a grass having improved characteristics, an endophyte having endophytic fungi which produce an insect-resistant alkaloid is artificially introduced into a grass by inoculation so that the endophyte lives in and infects the grass.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: January 30, 2001
    Assignee: Mayekawa Manufacturing Co., Ltd.
    Inventors: Naoya Hiruma, Satoshi Shinozaki
  • Patent number: 6177613
    Abstract: The present invention provides a composition and method for regulating expression of heterologous nucleotide sequences in a plant. The composition is a novel nucleic acid sequence for a seed-preferred promoter. A method for expressing a heterologous nucleotide sequence in a plant using the promoter sequence is also provided. The method comprises transforming a plant cell to contain a heterologous nucleotide sequence operably linked to the seed-preferred promoter of the present invention and regenerating a stably transformed plant from the transformed plant cell.
    Type: Grant
    Filed: January 8, 1999
    Date of Patent: January 23, 2001
    Assignee: Pioneer Hi-Bred International, Inc.
    Inventors: Sean J. Coughlan, Ronnie J. Winfrey, Jr.